menu
    • menu
    [{"orgOrder":0,"company":"Lactiga","sponsor":"Kenox Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Collaboration","leadProduct":"LCTG-001","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Lactiga","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Lactiga \/ Lactiga","highestDevelopmentStatusID":"4","companyTruncated":"Lactiga \/ Lactiga"},{"orgOrder":0,"company":"Lactiga","sponsor":"1517 Fund","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CANADA","productType":"Antibody, Unconjugated","year":"2022","type":"Financing","leadProduct":"LCTG-001","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Lactiga","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lactiga \/ 1517 Fund","highestDevelopmentStatusID":"4","companyTruncated":"Lactiga \/ 1517 Fund"},{"orgOrder":0,"company":"Lactiga","sponsor":"Icahn School of Medicine","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Antibody, Unconjugated","year":"2020","type":"Collaboration","leadProduct":"LCTG-001","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Lactiga","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lactiga \/ Icahn School of Medicine","highestDevelopmentStatusID":"4","companyTruncated":"Lactiga \/ Icahn School of Medicine"},{"orgOrder":0,"company":"Lactiga","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Antibody, Unconjugated","year":"2025","type":"Funding","leadProduct":"LCTG-003","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Lactiga","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lactiga \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"Lactiga \/ National Institutes of Health"}]

    Find Clinical Drug Pipeline Developments & Deals by Lactiga

    Menu

    Lactiga

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Lactiga

                            Canada arrow
                            AAPS
                            Not Confirmed

                            Lactiga

                            Canada arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : LCTG-003

                            Therapeutic Area : Gastroenterology

                            Study Phase : Preclinical

                            Sponsor : National Institutes of Health

                            Deal Size : Undisclosed

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Lactiga Wins NIH Backing for First-in-Class Breastmilk-Derived Antibody in IBD

                            Details : The funding will advance the development of its secretory IgA (sIgA) antibody for inflammatory bowel disease (IBD).

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Undisclosed

                            September 04, 2025

                            Lead Product(s) : LCTG-003

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Preclinical

                            Sponsor : National Institutes of Health

                            Deal Size : Undisclosed

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Lactiga

                            Canada arrow
                            AAPS
                            Not Confirmed

                            Lactiga

                            Canada arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : LCTG-001

                            Therapeutic Area : Immunology

                            Study Phase : Preclinical

                            Recipient : Kenox Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Kenox Partners with Lactiga to Advance Mucosal-Targeted Immunotherapy

                            Details : The collaboration will leverage Kenox extensive expertise in nasal and inhaled pharmaceutical development of LCTG-001. It is being evaluated for mucosal-targeted Secretory IgA.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Undisclosed

                            March 10, 2025

                            Lead Product(s) : LCTG-001

                            Therapeutic Area : Immunology

                            Highest Development Status : Preclinical

                            Recipient : Kenox Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Lactiga

                            Canada arrow
                            AAPS
                            Not Confirmed

                            Lactiga

                            Canada arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : LCTG-001

                            Therapeutic Area : Immunology

                            Study Phase : Preclinical

                            Sponsor : 1517 Fund

                            Deal Size : $1.6 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Lactiga Therapeutics Raises $1.6M USD in Oversubscribed Pre-Seed Round, Secures $350k in Research Grants

                            Details : The company plans to use the raised capital, grants, and awards to complete its preclinical studies for Lactiga’s two primary development programs, LCTG-001 (for patients with Common Variable Immunodeficiency) and LCTG-002 (for patients with COVID-19 a...

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Undisclosed

                            September 21, 2022

                            Lead Product(s) : LCTG-001

                            Therapeutic Area : Immunology

                            Highest Development Status : Preclinical

                            Sponsor : 1517 Fund

                            Deal Size : $1.6 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Lactiga

                            Canada arrow
                            AAPS
                            Not Confirmed

                            Lactiga

                            Canada arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : LCTG-001

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : Icahn School of Medicine

                            Deal Size : $2.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Lactiga Announces NIH-Funded Partnership with Mount Sinai to Advance its Patented Biologic for COVID-19 Treatm...

                            Details : Lactiga entered a collaboration agreement with the Icahn School of Medicine at Mount Sinai to advance preclinical research into LCTG-001 as a potential treatment for COVID-19 patients. Partners secured an NIH R01 Emergency Award of over $2MM to advance t...

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Undisclosed

                            October 14, 2020

                            Lead Product(s) : LCTG-001

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Icahn School of Medicine

                            Deal Size : $2.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth